ArticleBMC cancer2024

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.

Eric D Whitman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.